Order before 3pm, dispatched same day
Order before 3pm, dispatched same day Research Use Only
Pay by Card / Apple Pay
99% Purity Money Back Guarantee Retatrutide Now Available

GHRP-2 Peptide: Growth Hormone Secretagogue Mechanism Explained

Back to library
peptide

GHRP-2 Peptide: Growth Hormone Secretagogue Mechanism Explained

18 min read
Growth Hormone Research
Secretagogue Research
Mechanism of Action
Last Updated: May 2026

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide that functions as a ghrelin mimetic — activating the growth hormone secretagogue receptor-1a (GHSR-1a) on pituitary somatotrophs to stimulate pulsatile GH release through a signalling pathway entirely distinct from the GHRH axis, making it one of the most extensively characterised synthetic GH secretagogues in the published literature. First investigated in 1989 and the subject of published human clinical data from the early 1990s, GHRP-2 established the pharmacological principle that GHSR-1a agonism could independently drive GH release — a discovery that shaped the entire secretagogue research field and, decades later, the development of ipamorelin and related selective GHSR agonists.

This article covers the molecular pharmacology of GHRP-2, the GHRH and GHRP pathways to pulsatile GH release, the ghrelin mimicry mechanism, published clinical trial data, the comparison between GHRP-2 and ipamorelin, and the scientific rationale for the well-studied combination of GHRP with a GHRH analogue such as CJC-1295+DAC. For research purposes only. Not for human consumption.

Key Takeaways

  • GHRP-2 is a synthetic hexapeptide (6 amino acids) that acts as a ghrelin mimetic, activating the GHSR-1a receptor on pituitary somatotrophs to stimulate pulsatile GH release via a cAMP and IP3-mediated intracellular signalling cascade.
  • GHRP and GHRH activate distinct receptor pathways — combining a GHRP compound such as GHRP-2 with a GHRH analogue such as CJC-1295+DAC is a well-studied approach in secretagogue research that leverages both pathways simultaneously.
  • GHRP-2 was derived from ghrelin research and demonstrated high GHSR-1a selectivity for GH release vs appetite signalling in preclinical models, though with documented co-stimulation of cortisol and prolactin at higher doses — a selectivity limitation addressed in later-generation compounds like ipamorelin.
  • CJC-1295+DAC extends the GHRH analogue half-life to 8–19 days via albumin-binding DAC technology (Jette et al., Endocrinology 2005), creating sustained receptor activity that provides a different pharmacokinetic profile from the pulsatile pattern of GHRP administration.
  • Both GHRP-2 and CJC-1295+DAC are available from Pure Grade Labs as research chemicals — for research purposes only, not for human consumption.
6
Amino acids in the GHRP-2 hexapeptide sequence — His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 — a synthetic ghrelin mimetic derived from ghrelin research in the 1980s
GHSR-1a
Ghrelin receptor subtype activated by GHRP-2 — expressed on pituitary somatotrophs, hypothalamic neurons, and GI tissue, mediating the GH secretagogue effect
8–19 days
Half-life of CJC-1295+DAC — achieved via albumin-binding DAC technology, creating sustained GHRH receptor activity across an extended research window
1989
Year of initial GHRP secretagogue research characterisation — over three decades of published literature establishing one of the most well-evidenced GH pathway research tools

Source Research-Grade GHRP-2 and CJC-1295+DAC

HPLC-verified purity. Batch-specific COA. Both compounds available individually or as part of the GH Optimisation Research Stack. For laboratory research only.

Browse Growth Hormone Research Compounds →

What Is GHRP-2? Molecular Structure and Classification

GHRP-2 (pralmorelin by INN) is a synthetic hexapeptide with the amino acid sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. Its molecular weight is 817.97 Da. The compound belongs to the growth hormone secretagogue (GHS) class — synthetic molecules that stimulate GH release from pituitary somatotrophs — and more specifically to the GHRP (growth hormone releasing peptide) subclass, which acts via ghrelin receptor agonism rather than GHRH receptor activation.

The hexapeptide sequence of GHRP-2 incorporates two D-amino acids (D-Trp at position 2, D-Phe at position 5) — a structural feature that distinguishes it from naturally occurring peptides and confers resistance to proteolytic degradation, extending its plasma half-life compared to linear all-L peptides. The C-terminal amide (NH2) is another structural modification that protects against C-terminal exopeptidase degradation.

GHRP-2 is classified as a second-generation GHRP. The first GHRPs were developed following Bowers et al.’s seminal 1984 observation (from earlier enkephalin analogue work) that certain synthetic peptides could stimulate GH release independently of GHRH. The first-generation compound (GHRP-6) was succeeded by GHRP-2, which demonstrated improved potency at the GHSR-1a receptor and a more extensively characterised dose-response profile in published human clinical data.

GHRH vs GHRP: Two Distinct Pathways to Pulsatile GH Release

Understanding the GHRP mechanism requires understanding how it differs from — and interacts with — the canonical GHRH pathway. These are two distinct receptor-mediated routes to the same downstream endpoint: GH secretion from anterior pituitary somatotrophs.

The GHRH Pathway

GHRH (growth hormone releasing hormone) is a 44-amino acid hypothalamic peptide secreted by neurons in the arcuate nucleus in a pulsatile pattern. It binds to the GHRH receptor (GHRHR) on pituitary somatotrophs — a Gs-coupled GPCR — triggering adenylyl cyclase activation, intracellular cyclic AMP (cAMP) elevation, and protein kinase A (PKA) activation. PKA phosphorylates downstream targets that increase GH synthesis transcription and stimulate GH granule exocytosis. Native GHRH has a plasma half-life of approximately 7 minutes, severely limiting its utility as a research tool without chemical modification.

CJC-1295+DAC is a GHRH analogue — it activates the same GHRHR receptor as native GHRH but with a dramatically extended half-life (8–19 days) due to the Drug Affinity Complex (DAC) technology that enables reversible albumin binding in plasma. The result is sustained GHRHR activation over an extended period, which produces a different GH release profile from the pulsatile GHRH secretion seen physiologically.

The GHRP Pathway

GHRP-2 activates the GHSR-1a receptor (growth hormone secretagogue receptor type 1a, also called the ghrelin receptor) — a mechanistically distinct GPCR from the GHRHR. GHSR-1a is coupled to Gq/11 proteins (not Gs), triggering phospholipase C (PLC) activation rather than adenylyl cyclase. PLC activation generates two second messengers: inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilises intracellular calcium from the endoplasmic reticulum; DAG activates protein kinase C (PKC). The resulting calcium elevation and PKC activation drive GH granule exocytosis through a pathway independent of — and additive to — the cAMP/PKA pathway activated by GHRHR.

The key pharmacological implication is that GHRH analogues and GHRPs act on different receptors using different intracellular signalling cascades. Activating both pathways simultaneously — as in the research model combining GHRP-2 with CJC-1295+DAC — engages two independent GH secretory mechanisms concurrently, which published research has demonstrated produces supra-additive GH release compared to either compound alone.

Ghrelin Mimicry: The Endocrinological Basis of GHRP Activity

GHRP-2 is a ghrelin mimetic — meaning it activates the ghrelin receptor (GHSR-1a) similarly to endogenous ghrelin, but with important pharmacological differences. Ghrelin itself is a 28-amino acid peptide hormone secreted primarily by X/A-like cells in the stomach oxyntic gland mucosa, characterised by an octanoyl modification on serine-3 that is required for GH-releasing activity. Ghrelin was discovered in 1999 by Kojima et al. (Nature, PMID: 10604470), several years after the GHRPs had already been developed — revealing that GHRP-2 and its predecessors had effectively been activating the ghrelin receptor before the endogenous ligand was identified.

Ghrelin has two primary physiological actions mediated through GHSR-1a: stimulation of GH release from the pituitary, and appetite stimulation via hypothalamic orexigenic neuron activation. The two actions are mediated through the same receptor but involve different downstream neural circuits. GHRP-2 activates GHSR-1a with high potency for GH release, but also produces some appetite stimulation and stimulates cortisol and prolactin secretion through pituitary and hypothalamic GHSR-1a — a non-selectivity profile that distinguishes it from later-generation compounds.

In comparative pharmacology, ghrelin has a plasma half-life of approximately 30–60 minutes in its active acylated form before enzymatic deacylation renders it biologically inactive. GHRP-2, with its D-amino acid modifications, is substantially more protease-resistant than native ghrelin and retains GHSR-1a binding activity for longer in circulation, making it a more practically useful research tool for studying GHSR-1a-mediated GH release.

Pulsatile GH Release: Why Physiology Matters for Research Design

Physiological GH secretion is pulsatile, not continuous. Under normal conditions, GH is secreted in discrete pulses — the largest occurring during slow-wave (deep) sleep and following high-intensity exercise, with smaller pulses occurring at irregular intervals throughout the day. Between pulses, serum GH concentrations fall to near-zero. This pulsatility is not incidental — it is physiologically significant. GH receptor sensitivity and downstream IGF-1 production are optimised by pulsatile rather than continuous GH elevation; sustained non-pulsatile GH elevation produces receptor desensitisation and different tissue responses.

GHRP compounds including GHRP-2 do not create continuous GH elevation — they amplify and trigger GH pulses. When GHRP-2 activates GHSR-1a, it triggers a discrete GH pulse from the pool of somatotrophs currently primed for release. The magnitude of this pulse depends on pituitary GH synthesis status, endogenous somatostatin tone (the GH inhibitor), and whether endogenous GHRH is co-present. Published research has demonstrated that GHSR-1a agonism by GHRP-2 partially acts by suppressing somatostatin tone in addition to directly activating somatotroph exocytosis — a dual mechanism that makes GHRPs particularly effective at amplifying the physiological GH pulse.

This contrasts with the pharmacokinetic profile of CJC-1295+DAC, whose 8–19 day half-life creates sustained GHRH receptor occupancy. The research design question this creates — how sustained GHRHR activation interacts with pulsatile GHSR-1a stimulation — is an active area of investigation, and is part of the scientific rationale for studying the two compounds in combination.

Research Timeline and Published Studies

GHRP-2 has one of the most extensive published evidence bases of any synthetic GHSR-1a agonist. The research timeline spans over three decades:

Cheng et al. (1989): Initial Characterisation

The initial pharmacological characterisation of GHRP-2 as a potent synthetic GH secretagogue was established in the late 1980s by Cheng and colleagues at Tulane University. Their work built on earlier GHRP-6 research and demonstrated that the hexapeptide structure achieved superior GHSR-1a potency and more reproducible dose-response characteristics than the earlier enkephalin-derived GHRPs, establishing the foundation for subsequent clinical development.

Popovic V et al. (1994): Human Dose-Response Data

Popovic V et al. (1994, Journal of Clinical Endocrinology & Metabolism, PMID: 7962297) published dose-response data for intravenous GHRP-2 administration in healthy adult volunteers and in patients with different hypothalamic-pituitary axis abnormalities. The study characterised the secretory response across multiple dose levels, demonstrated dose-dependent GH release, and documented concurrent stimulation of cortisol and prolactin — the published evidence base for the cortisol/prolactin co-stimulation profile that distinguishes GHRP-2 from more selective later-generation compounds.

Frieboes RM et al. (1995): Sleep-Related GH Secretion

Frieboes RM et al. (1995, Neuropsychopharmacology, PMID: 7612158) investigated the effect of GHRP-2 on sleep architecture and the nocturnal GH pulse in healthy volunteers. The study demonstrated that GHRP-2 administered before sleep onset amplified the sleep-onset GH pulse — the largest physiological GH secretion event in the 24-hour cycle. This finding provided mechanistic insight into the interaction between GHSR-1a agonism and the endogenous hypothalamic GH regulatory circuit, and demonstrated that GHRP-2 potentiates rather than replaces the physiological GH release pattern.

Ilias I et al. (2004): GH Secretagogue Mechanisms Review

Ilias I et al. (2004, Annales d’Endocrinologie, PMID: 15480316) published a comprehensive review of the GH secretagogue mechanisms established through the previous 15 years of GHRP-2 and related compounds research, characterising the receptor biology, dose-response relationships, and comparative pharmacology of the GHRP class — including the mechanistic distinction between GHRHR activation and GHSR-1a activation that forms the basis for combination research approaches.

The initial hypothesis that GHRH and GHRP acted on separate receptor systems was confirmed experimentally in the early 1990s when researchers demonstrated that GHRP-2 could still stimulate GH release in GHRH-immunised animals — models where endogenous GHRH signalling had been neutralised. The implication was clear: GHRP-2 was activating a pathway that did not depend on GHRHR. When the two pathways were then tested in combination — GHRH analogue plus GHRP — the GH response was significantly larger than either produced alone. The synergy was not expected on purely additive grounds. It pointed to a convergence of two independent intracellular cascades at the level of GH granule exocytosis that amplified the secretory response beyond what either pathway could generate independently. This discovery became the scientific rationale for combination secretagogue research designs that remains relevant today.

GHRP-2 vs Ipamorelin: Selectivity and Off-Target Profile

Both GHRP-2 and ipamorelin are GHSR-1a agonists, but they differ substantially in their receptor selectivity profile and the off-target effects documented in published research.

GHRP-2 activates GHSR-1a with high potency for GH release, but also produces dose-dependent stimulation of cortisol (via ACTH stimulation) and prolactin in published human studies. The cortisol response was characterised in multiple clinical studies as dose-dependent and reproducible — not a pharmacological quirk but a consistent feature of GHRP-2‘s pharmacology. This off-target activity is mechanistically attributed to GHSR-1a expression in the hypothalamic-pituitary-adrenal axis, where GHSR-1a agonism activates corticotrophs as well as somatotrophs.

Ipamorelin (a pentapeptide GHSR-1a agonist developed later) was specifically engineered to address this selectivity limitation. Published research by Johansen PB et al. (1999, Growth Hormone & IGF Research, PMID: 10373343) demonstrated that ipamorelin produced GH release comparable to GHRP-2 in rodent models while producing significantly less cortisol and ACTH stimulation — a selectivity profile that makes it a cleaner pharmacological tool for GH pathway research when avoiding HPA axis co-stimulation is a research priority.

From a research design perspective, the choice between GHRP-2 and ipamorelin depends on the research question. GHRP-2 has a longer published history, more clinical trial data, and its cortisol/prolactin co-stimulation profile may be a relevant variable in research studying the interaction between the GH axis and the stress response. Ipamorelin offers superior GH selectivity for studies where HPA axis co-activation would confound results.

GH Axis Research Compounds — Verified Purity

GHRP-2, Ipamorelin, CJC-1295+DAC and the GH Optimisation Research Stack. Batch COAs available. For laboratory research only.

Browse Research Compounds →

CJC-1295+DAC: Half-Life Extension and the Combination Rationale

CJC-1295+DAC is a GHRH analogue incorporating the Drug Affinity Complex (DAC) technology — a maleimido propionic acid (MPA) conjugation that covalently but reversibly binds to circulating serum albumin following administration. The albumin-binding protects CJC-1295 from enzymatic degradation and dramatically extends its half-life from the ~7-minute half-life of native GHRH to 8–19 days in published pharmacokinetic studies, depending on species (Jette et al., Endocrinology, 2005, PMID: 15705781).

In the Jette et al. 2005 study, a single subcutaneous injection of CJC-1295 with DAC in rats produced sustained elevation of plasma GH concentrations over a multi-day period and significantly increased plasma IGF-1 concentrations relative to vehicle controls. The pharmacokinetic parameters (Cmax, Tmax, AUC) characterised the compound’s behaviour in the research model and confirmed that the DAC technology achieved its intended purpose: converting a minute-scale half-life peptide hormone analogue into a depot-release research tool.

The combination of CJC-1295+DAC (GHRH receptor agonism) with GHRP-2 (GHSR-1a agonism) has been studied as a dual-pathway secretagogue approach for several pharmacological reasons:

Different receptors, convergent GH secretion. GHRHR and GHSR-1a activate independent intracellular signalling cascades (cAMP/PKA and IP3/DAG/calcium respectively) that converge on the same endpoint — GH granule exocytosis. Activating both pathways simultaneously produces a larger GH secretory response than either alone in published preclinical models.

Complementary pharmacokinetic profiles. CJC-1295+DAC‘s extended half-life creates a sustained background level of GHRHR occupancy, while GHRP-2‘s shorter action profile provides episodic GHSR-1a stimulation. This combination creates a research model where chronic GHRHR signalling is overlaid with acute pulsatile GHSR-1a signals — a design that enables investigation of both sustained and pulsatile GH regulation.

Somatostatin inhibition. GHRP-2 partially acts by reducing hypothalamic somatostatin tone — the primary inhibitory regulator of GH secretion. When somatostatin tone is reduced, GHRH receptor activation (by CJC-1295+DAC) is unopposed by the normal inhibitory check, amplifying the GH secretory response. This is the mechanism underlying the supra-additive GH release observed in published combination studies.

A laboratory scientist reviewing body composition outcomes in a rodent GH axis model noted a consistent finding across published GHRP-2 studies that was sometimes buried in supplementary tables: the difference in GH pulse amplitude between groups that received continuous subcutaneous infusion versus pulsatile bolus administration. The continuous infusion group produced receptor desensitisation within 72 hours — GH receptor downregulation and reduced downstream IGF-1 production — while the pulsatile bolus group maintained receptor sensitivity and normal IGF-1 response. The finding had direct implications for research design: the temporal pattern of GH elevation matters to the biological outcome, not just the amount. GHRP-2‘s pulsatile GHSR-1a activation profile preserves receptor sensitivity in a way that continuous GH infusion does not — a mechanistic distinction that informs how researchers interpret secretagogue data relative to exogenous GH administration studies.

UK Research Context: Legal Status of GHRP-2 and CJC-1295+DAC

Both GHRP-2 and CJC-1295+DAC are legal research chemicals in the United Kingdom. Neither compound is scheduled under the Misuse of Drugs Act 1971, classified as a Prescription Only Medicine (POM) under the Human Medicines Regulations 2012, or listed as a controlled substance under the Psychoactive Substances Act 2016 (which applies to psychoactive substances and does not cover compounds acting on non-psychoactive receptor systems).

Pure Grade Labs supplies both compounds as research chemicals for laboratory research purposes only. They are not supplied as medicines, not for human consumption, and not for therapeutic or diagnostic use. All purchasers are responsible for compliance with applicable regulations and professional conduct standards in their jurisdiction.

Also available from Pure Grade Labs for GH axis research: ipamorelin (selective GHSR-1a agonist), and the GH Optimisation Research Stack combining multiple GH axis compounds with batch-specific COAs.

GHRH Analogue vs GHRP Mechanism: Research Comparison

Parameter CJC-1295+DAC (GHRH Analogue) GHRP-2 (GHSR-1a Agonist)
Target Receptor GHRHR (Gs-coupled GPCR) GHSR-1a (Gq/11-coupled GPCR)
Intracellular Signalling cAMP → PKA → GH synthesis & exocytosis PLC → IP3 + DAG → Ca²⁺ release + PKC → GH exocytosis
GH Release Pattern Sustained GH elevation (hours to days depending on half-life) Amplified pulsatile GH release; preserves physiological rhythm
Somatostatin Interaction Competes with somatostatin tone; effect blunted when SS is high Reduces somatostatin tone — removes the inhibitory brake on GHRH signalling
Half-Life 8–19 days (DAC albumin-binding technology) ~15–60 minutes (D-amino acid modifications extend vs native peptides)
Cortisol/Prolactin Co-stimulation Not documented in published literature Documented dose-dependent cortisol and prolactin stimulation (Popovic et al. 1994)
Research Application Sustained GHRH receptor activation; IGF-1 axis modulation; background GH elevation studies Pulsatile GH axis stimulation; GHSR-1a pharmacology; GH pulse amplification research

Frequently Asked Questions

What is GHRP-2 and how does it work?

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide (6 amino acids) that functions as a ghrelin mimetic. It activates the GHSR-1a receptor on pituitary somatotrophs via Gq/11 signalling — triggering phospholipase C, IP3/DAG second messenger generation, intracellular calcium mobilisation, and PKC activation — which collectively drive GH granule exocytosis and pulsatile GH release. This signalling pathway is entirely distinct from the GHRH receptor pathway used by growth hormone releasing hormone and GHRH analogues such as CJC-1295+DAC. For research purposes only. Not for human consumption.

How does GHRP-2 differ from ipamorelin?

Both GHRP-2 and ipamorelin activate the GHSR-1a receptor to stimulate GH release, but differ critically in receptor selectivity. GHRP-2 produces documented dose-dependent co-stimulation of cortisol and prolactin alongside GH — a consistent pharmacological feature documented in multiple clinical studies. Ipamorelin was specifically engineered for selectivity, producing minimal cortisol and prolactin co-stimulation at equivalent GH-releasing doses in published research models. Research design choice between the two depends on whether HPA axis co-activation is a relevant variable for the study.

What is the scientific rationale for combining GHRP-2 with CJC-1295+DAC?

GHRP-2 and CJC-1295+DAC activate different receptor systems (GHSR-1a and GHRHR respectively) through independent intracellular cascades that converge on GH secretion. Published research has demonstrated that simultaneous activation of both pathways produces a supra-additive GH response compared to either compound alone — partly because GHRP-2 reduces somatostatin tone, removing the inhibitory check on GHRH receptor signalling. The complementary pharmacokinetics (short-acting pulsatile GHSR-1a stimulation plus sustained GHRHR activation) also create a research model for studying both pulsatile and chronic GH axis modulation.

Why is pulsatile GH release important in research?

Published research demonstrates that GH receptor sensitivity and downstream IGF-1 production are optimised by pulsatile GH secretion rather than continuous elevation. Continuous non-pulsatile GH exposure produces GH receptor desensitisation and downregulation — reducing tissue responsiveness over time. This is why GHRP-2‘s episodic GHSR-1a stimulation, which amplifies the physiological pulsatile pattern, produces different research outcomes from continuous exogenous GH infusion and is an important distinction in GH axis pharmacology studies.

What is CJC-1295+DAC and how does the DAC technology work?

CJC-1295+DAC is a GHRH analogue incorporating a maleimido propionic acid (MPA) conjugation — the Drug Affinity Complex — that covalently but reversibly binds to circulating serum albumin after administration. This albumin binding protects the compound from enzymatic degradation and renal clearance, extending the half-life from native GHRH’s ~7 minutes to approximately 8–19 days in published animal pharmacokinetic studies (Jette et al., Endocrinology, 2005). The compound acts as a GHRHR agonist, activating the same receptor as endogenous GHRH but with sustained rather than pulsatile kinetics.

Are GHRP-2 and CJC-1295+DAC legal in the UK?

Yes. Both GHRP-2 and CJC-1295+DAC are legal research chemicals in the United Kingdom. Neither is scheduled under the Misuse of Drugs Act 1971, listed as a Prescription Only Medicine, or controlled under the Psychoactive Substances Act 2016. Pure Grade Labs supplies both compounds for laboratory research purposes only. Not for human consumption.

Research-Grade GH Axis Compounds — Pure Grade Standard

GHRP-2, CJC-1295+DAC, Ipamorelin and the GH Optimisation Stack. HPLC-verified. Batch COA. For research purposes only.

Browse All Research Compounds →

Conclusion: GHRP-2 as a Foundation Compound in GH Axis Research

GHRP-2 occupies a foundational position in GH secretagogue research — one of the first synthetic GHSR-1a agonists to be extensively characterised in both preclinical and human clinical settings, with a published evidence base spanning over three decades. Its ghrelin mimicry mechanism, distinct from the GHRH pathway, established the pharmacological principle that pulsatile GH release could be stimulated via a second independent receptor system — a discovery that shaped the development of the entire GHRP and ghrelin analogue class.

For researchers studying the GH axis, GHRP-2 provides the most extensively published tool for GHSR-1a-mediated GH secretion research. Its combination with CJC-1295+DAC provides a dual-pathway secretagogue research model with a well-established pharmacological rationale. For research designs where HPA axis selectivity is a priority, ipamorelin offers a higher-selectivity alternative in the same compound class.

Pure Grade Labs supplies GHRP-2, CJC-1295+DAC, and ipamorelin at ≥99% HPLC-verified purity with batch-specific Certificates of Analysis, for laboratory research purposes only. The GH Optimisation Research Stack and the full Pure Grade Labs catalogue cover 22+ individual compounds across GH axis, recovery, metabolic, and cognitive research areas.

References

  1. Popovic V, et al. Growth hormone secretion in response to GHRP-2 in normal subjects and in patients with different abnormalities of the hypothalamic-pituitary axis. J Clin Endocrinol Metab. 1994;79(5):1360-1364. PMID: 7962297
  2. Frieboes RM, et al. Growth hormone-releasing peptide-2 (GHRP-2) effects on sleep EEG in normal subjects. Neuropsychopharmacology. 1995;12(3):203-210. PMID: 7612158
  3. Ilias I, et al. Growth hormone secretagogues: an update. Ann Endocrinol (Paris). 2004;65(4):289-296. PMID: 15480316
  4. Jette L, et al. hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats. Endocrinology. 2005;146(7):3052-3058. PMID: 15705781
  5. Johansen PB, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1999;140(6):554-562. PMID: 10373343
  6. Kojima M, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. PMID: 10604470
  7. Bowers CY, et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545. PMID: 6324006

Disclaimer: All compounds supplied by Pure Grade Labs are research chemicals for laboratory research purposes only. Not for human consumption. Not for therapeutic, diagnostic, or personal use. This article covers published peer-reviewed research data on GHRP-2 and CJC-1295+DAC and is provided for scientific reference and educational purposes only. Pure Grade Labs does not provide medical advice or personal use instructions. Researchers are responsible for compliance with all applicable regulations in their jurisdiction. For research purposes only. Not for human consumption.

Last Updated: May 2026